<DOC>
	<DOC>NCT02340195</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics properties of idalopirdine following multiple dosing in patients with renal impairment and compare to those in healthy subjects</brief_summary>
	<brief_title>Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Men or women aged between 50 and 75 years (inclusive) BMI ≥18.5 kg/m2 and ≤32 kg/m2 at the Screening Visit. Group A: Patients with severe renal impairment renal impairment (creatinine clearance (ClCr) ≤29 mL/min) Group B: Healthy subjects with normal kidney function (creatinine clearance (ClCr) ≥90 mL/min, inclusive) Group C: Patients with moderate renal impairment ((creatinine clearance between 30 59 mL/min, inclusive) Group D: Patients with mild renal impairment (Creatinine clearance between 60 89 mL/min, inclusive) •The subject has taken disallowed medication &lt;1 week prior to the first dose of IMP or &lt;5 halflives prior to the first dose of IMP for any disallowed medication taken, whichever is longer) Other protocol defined inclusion and exclusion criteria do apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Kidney impairment</keyword>
</DOC>